List of Excipients in Branded Drug PROTONIX

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Wyeth Pharmaceuticals LLC a subsidiary of Pfizer Inc	PROTONIX	pantoprazole sodium	0008-0843	CALCIUM STEARATE
Wyeth Pharmaceuticals LLC a subsidiary of Pfizer Inc	PROTONIX	pantoprazole sodium	0008-0843	CROSPOVIDONE
Wyeth Pharmaceuticals LLC a subsidiary of Pfizer Inc	PROTONIX	pantoprazole sodium	0008-0843	FERRIC OXIDE YELLOW
Wyeth Pharmaceuticals LLC a subsidiary of Pfizer Inc	PROTONIX	pantoprazole sodium	0008-0843	HYPROMELLOSE 2910
Wyeth Pharmaceuticals LLC a subsidiary of Pfizer Inc	PROTONIX	pantoprazole sodium	0008-0843	MANNITOL

Protonix Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

PROTONIX is the U.S. brand for pantoprazole sodium, a proton-pump inhibitor available primarily as delayed-release tablets and an intravenous formulation. Its commercial differentiation depends less on the active ingredient than on acid protection, dosage-form performance, supply reliability, and channel-specific convenience. The strongest opportunities are generic delayed-release tablets, hospital IV products, pediatric or dysphagia-friendly presentations, and excipient systems that improve stability without changing the approved release profile.

What excipients are used in Protonix delayed-release tablets?

PROTONIX delayed-release tablets use an enteric-coated formulation designed to prevent pantoprazole degradation in gastric acid and release the drug in the intestine. The FDA label identifies the following inactive ingredients for the 20 mg and 40 mg tablets.[1]

Formulation component	Reported excipients	Primary function
Tablet core	Mannitol	Diluent and tablet-body former
Tablet core	Crospovidone	Superdisintegrant
Tablet core	Povidone	Binder
Tablet core	Calcium stearate	Lubricant
Seal or subcoat	Hypromellose, povidone	Moisture and chemical protection
Film coating	Titanium dioxide, yellow ferric oxide	Opacity and color
Film coating	Propylene glycol	Plasticizer
Enteric coating	Methacrylic acid copolymer	Acid-resistant intestinal release
Enteric coating	Triethyl citrate	Plasticizer
Enteric coating	Polysorbate 80, sodium lauryl sulfate	Wetting and coating-process aids

The formulation is a multipart coating system rather than a simple immediate-release tablet. The core must disintegrate after intestinal release, while the coating must remain intact under gastric conditions. The product should not be crushed, chewed, or split because damage to the coating can alter delivery and expose pantoprazole to acid.[1]

Why is the Protonix enteric coating commercially important?

Pantoprazole is acid-labile. The enteric coating is therefore a critical quality attribute, not a cosmetic layer. A commercial copy must control:

• Gastric-acid resistance
• Intestinal release timing
• Coating weight gain and uniformity
• Core porosity and disintegration
• Residual moisture
• Polymer grade and plasticizer ratio
• Stability under accelerated and long-term conditions
• Dissolution performance across pH conditions

A lower-cost formulation that uses a different polymer system can still be commercially viable, but it must demonstrate comparable dissolution and bioequivalence. The principal technical risk is failure at the interface between the tablet core, seal coat, and enteric film.

What excipients are used in Protonix IV?

PROTONIX I.V. is a lyophilized pantoprazole sodium product. The U.S. prescribing information identifies pantoprazole sodium and edetate disodium as formulation components, with sodium hydroxide used for pH adjustment.[2]

Component	Function
Pantoprazole sodium	Active pharmaceutical ingredient
Edetate disodium	Chelating agent and stability aid
Sodium hydroxide	pH adjustment and alkaline stabilization

The IV formulation is supplied for reconstitution before administration. Commercial performance depends on cake structure, reconstitution time, solution clarity, pH, particulate control, container closure integrity, and compatibility with infusion systems.

Edetate disodium is strategically relevant because trace metals can contribute to degradation. The formulation also requires control of alkaline conditions because pantoprazole stability is highly pH-dependent. A substitute excipient system must preserve chemical stability while avoiding precipitation, discoloration, excessive osmolality, or compatibility problems with common diluents.

What excipient strategy best supports a generic Protonix tablet?

The lowest-risk strategy is a conservative, label-aligned formulation using established pharmaceutical excipients and a conventional methacrylic-acid-copolymer enteric system.

Recommended formulation priorities

1. Preserve the delayed-release mechanism.
   The product should reproduce the reference product’s acid resistance and intestinal dissolution profile.

2. Use compendial, widely sourced excipients.
   Mannitol, crospovidone, povidone, calcium stearate, hypromellose, triethyl citrate, and methacrylic acid copolymers have broad supplier availability.

3. Minimize excipient novelty.
   New excipients can create regulatory and clinical justification requirements, increase supplier qualification costs, and complicate scale-up.

4. Control moisture and peroxide exposure.
   Excipient water content, residual solvents, peroxide levels, and storage humidity should be treated as stability variables.

5. Design for coating robustness.
   The coating process should tolerate commercial-scale variation in spray rate, inlet temperature, atomization, bed temperature, and tablet movement.

6. Avoid unnecessary color changes.
   A different color may be acceptable for an ANDA product, but it increases product-identification and manufacturing complexity.

Which excipients offer the greatest supply-chain leverage?

The main cost and supply risks are unlikely to come from mannitol or calcium stearate. Greater leverage exists in:

• Methacrylic acid copolymer grades
• Triethyl citrate
• Hypromellose
• Crospovidone
• High-purity edetate disodium for IV products
• Titanium dioxide and iron-oxide color systems
• Specialty coating premixes

A dual-source strategy is practical for most tablet excipients. Enteric polymers should be qualified from more than one supplier where possible, but equivalence cannot be assumed between polymer grades. Viscosity, neutralization behavior, particle size, solids content, and film formation can affect dissolution.

What commercial opportunities exist for Protonix excipients?

Generic delayed-release tablets

The largest opportunity is a conventional generic product in 20 mg and 40 mg strengths. Pantoprazole is an established molecule with broad prescribing history and a mature generic market. Commercial differentiation is likely to depend on manufacturing cost, supply continuity, wholesaler access, and hospital or institutional contracts rather than clinical superiority.

Potential advantages include:

• Lower tablet weight
• Faster coating cycle
• Reduced solvent use
• Improved yield
• Fewer coating defects
• Dual-source excipients
• Smaller minimum production batches
• Private-label or regional distribution

A formulation that achieves equivalent performance with a lower-cost coating process can improve gross margin without changing the product’s clinical positioning.

Hospital IV supply

Pantoprazole IV creates a separate opportunity because hospitals value reliable supply, reconstitution performance, and contract pricing. The commercial barriers include sterile manufacturing, lyophilization capacity, container-closure validation, particulate control, and pharmacy compatibility data.

An IV supplier may compete through:

• Ready-to-reconstitute packaging
• Lower fill-volume burden
• Improved vial presentation
• Consistent availability
• 20 mg or 40 mg institutional presentations
• Contract-manufactured hospital supply
• Reduced preparation time

The IV segment has higher manufacturing barriers than oral tablets but can support stronger supplier relationships.

Pediatric and dysphagia-oriented formulations

The conventional tablet is unsuitable for patients who cannot swallow or who require administration through feeding tubes. Commercial opportunities include:

• Delayed-release granules
• Sprinkle capsules
• Sachets for oral suspension
• Tube-compatible formulations
• Pediatric dose flexibility
• Unit-dose packaging

These products cannot simply be created by crushing PROTONIX tablets. The enteric protection must be rebuilt using coated granules, multiparticulates, or another validated delivery system. The regulatory pathway may differ from a standard ANDA depending on the reference product and the proposed dosage form.

Excipient supplier opportunities

Excipient manufacturers can compete by offering:

• Low-peroxide grades
• Low-moisture grades
• Prequalified enteric-coating systems
• Ready-to-use aqueous coating dispersions
• Technical support for scale-up
• Consistent particle-size distributions
• Regional inventory and dual sourcing
• Regulatory documentation packages

The strongest supplier proposition is not simply a lower unit price. It is a validated package that reduces coating development time, failed batches, and post-approval change risk.

How does Protonix compare with competing proton-pump inhibitors?

Pantoprazole competes with omeprazole, esomeprazole, lansoprazole, and rabeprazole. All require formulation strategies that address acid stability, but the excipient and release designs differ by product.

Product	Active ingredient	Common dosage-form strategy	Commercial implication
PROTONIX	Pantoprazole sodium	Enteric-coated delayed-release tablet; IV lyophilized product	Strong generic and institutional opportunities
Prilosec	Omeprazole	Delayed-release capsule or tablet presentations	Mature generic market; multiparticulate competition
Nexium	Esomeprazole magnesium	Delayed-release tablet, capsule, granules, IV	Broader lifecycle-formulation benchmark
Prevacid	Lansoprazole	Delayed-release capsule and orally disintegrating forms	Stronger precedent for patient-friendly presentations
AcipHex	Rabeprazole sodium	Delayed-release tablet	Smaller market opportunity but similar coating requirements

Pantoprazole’s IV availability gives it a distinct institutional position relative to some oral-only generic competitors. Its oral tablet opportunity is less differentiated and more exposed to price competition.

When does Protonix lose exclusivity?

PROTONIX no longer has meaningful new-chemical-entity exclusivity in the United States. The product was approved in the early 2000s, and generic pantoprazole products have been marketed for years. The relevant commercial question is therefore not loss of basic exclusivity but the remaining value of brand recognition, institutional contracts, supply reliability, and any current listed patents or regulatory protections.

The FDA Orange Book remains the controlling source for current patent listings, pediatric exclusivity, and regulatory exclusivity associated with a drug application.[3] Historical pantoprazole compound and formulation patents expired long ago or ceased to prevent routine generic entry. Any current patent analysis should separate:

• Expired compound patents
• Expired delayed-release or formulation patents
• Method-of-use patents
• Any later-listed patents
• Pediatric exclusivity
• Litigation-related market-entry restrictions

What patents protect Protonix and its excipient system?

The core commercial protection for PROTONIX historically involved pantoprazole chemistry, pharmaceutical compositions, and delayed-release delivery. Excipients themselves generally do not create meaningful protection when they are conventional materials such as mannitol, crospovidone, povidone, hypromellose, or methacrylic acid copolymers.

Potentially protectable subject matter can include:

• Specific polymer combinations
• Coating-layer architecture
• Defined dissolution profiles
• Stabilizing alkaline microenvironments
• Particular particle or granule structures
• Manufacturing parameters
• IV lyophilization conditions
• Container-closure systems
• New pediatric or tube-administration formulations

For a generic manufacturer, the main patent risk is typically the claimed dosage form or method of use, not ownership of the individual excipients. Because Protonix is a mature product, the principal barrier is likely to be development execution rather than a foundational patent blockade.

Are there Paragraph IV challenges to Protonix?

Generic pantoprazole products have historically entered through the ANDA pathway, which commonly includes patent certifications under Paragraph III or Paragraph IV. A Paragraph IV certification alleges that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The filing can trigger patent litigation and a potential 30-month stay under the Hatch-Waxman framework.[4]

For a current launch assessment, the relevant commercial variables are:

• The specific ANDA applicant
• The patents listed against the reference product
• Certification type
• Filing date
• Litigation status
• Any 180-day exclusivity
• Settlement restrictions
• Tentative and final approval dates

No generic applicant should assume that an old Protonix patent automatically blocks a new formulation. The risk depends on the exact claim scope and the proposed product’s dosage form.

What regulatory status does Protonix have?

The FDA approved PROTONIX delayed-release tablets under NDA 020987 and PROTONIX I.V. under NDA 020988.[1,2] The products are prescription proton-pump inhibitors used for acid-related disorders, including erosive esophagitis associated with gastroesophageal reflux disease and pathological hypersecretory conditions.

A conventional generic tablet generally follows the ANDA route and must demonstrate pharmaceutical equivalence and bioequivalence. A new dosage form, new route, or materially different formulation may require a 505(b)(2) application rather than a conventional ANDA.[5]

The most important regulatory quality attributes are:

• Assay and content uniformity
• Related substances
• Acid-stage resistance
• Buffer-stage dissolution
• Stability
• Microbial quality
• Tablet mechanical strength
• Coating uniformity
• IV reconstitution and particulate limits

What generic launch risks exist for Protonix?

Risk	Commercial effect	Mitigation
Coating failure	Batch rejection or delayed launch	Robust process design and scale-up studies
Pantoprazole degradation	Stability failure	Moisture, pH, oxygen, and excipient control
Polymer supply interruption	Production stoppage	Dual sourcing and qualified alternatives
Price erosion	Lower margins	Institutional contracts and efficient manufacturing
Dosage-form mismatch	ANDA or bioequivalence risk	Early regulatory classification
IV quality failure	Hospital withdrawal or contract loss	Strong sterile and lyophilization controls
Patient confusion	Medication errors	Clear color, imprint, and packaging differentiation
New excipient justification	Regulatory delay	Prefer established excipients

What is the commercial outlook for Protonix excipients?

The highest-probability opportunity is a cost-efficient generic delayed-release tablet using a conventional excipient system. The highest-margin opportunity may be a differentiated patient-friendly dosage form or a reliable hospital IV product, but both carry greater development and regulatory risk.

The most defensible excipient strategy is to:

• Maintain an established enteric-polymer platform.
• Qualify multiple suppliers for critical excipients.
• Control moisture and reactive impurities.
• Build dissolution testing around coating-process variability.
• Use formulation changes only when they create a measurable commercial advantage.
• Treat pediatric, tube-compatible, and ready-to-use presentations as separate development programs.

Key Takeaways

• PROTONIX contains pantoprazole sodium and relies on enteric protection to prevent gastric degradation.
• The oral tablet uses a conventional core plus seal-coat and methacrylic-acid-copolymer coating system.
• The IV product relies on pantoprazole sodium, edetate disodium, alkaline pH control, and lyophilization.
• Generic delayed-release tablets are the lowest-risk commercial opportunity.
• IV supply, pediatric formulations, granules, and tube-compatible products offer more differentiation but require greater investment.
• Excipient patents are generally less important than dosage-form, process, and dissolution claims.
• Protonix has no remaining new-chemical-entity exclusivity; current Orange Book listings and litigation records control any residual patent risk.
• Supply assurance for enteric polymers and sterile-manufacturing capacity can create more commercial value than small excipient-cost reductions.

FAQs

Can Protonix tablets be reformulated without mannitol?

Yes. Mannitol is a formulation excipient rather than the active ingredient. A substitute diluent may be used if the reformulated product meets manufacturing, stability, dissolution, and bioequivalence requirements.

Is a pantoprazole oral suspension automatically equivalent to Protonix tablets?

No. An oral suspension may require a different release mechanism, stability profile, administration instruction, and regulatory pathway. It is not automatically substitutable with the delayed-release tablet.

Which excipient is most critical to pantoprazole tablet performance?

The enteric polymer system is usually the most critical because it controls gastric resistance and intestinal release. Coating plasticizer, polymer grade, coating thickness, and process conditions are interdependent.

Can a manufacturer use the same excipient system for pantoprazole tablets and IV products?

No. The oral and IV products have different dosage-form requirements. Tablet excipients such as mannitol, crospovidone, and calcium stearate are not interchangeable with the sterile injectable formulation.

Does an excipient change alone create a new patent opportunity?

Usually not. A patentable opportunity is more likely when the excipient change produces a defined technical effect, such as improved stability, a new release profile, a novel multiparticulate structure, or improved tube administration.

References

1. U.S. Food and Drug Administration. (n.d.). PROTONIX (pantoprazole sodium) delayed-release tablets: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
2. U.S. Food and Drug Administration. (n.d.). PROTONIX I.V. (pantoprazole sodium) for injection: Prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
4. U.S. Food and Drug Administration. (2017). Guidance for industry: 180-day exclusivity when multiple ANDAs are submitted on the same day. https://www.fda.gov/media/102843/download
5. U.S. Food and Drug Administration. (2019). Applications covered by section 505(b)(2). https://www.fda.gov/drugs/development-resources/applications-covered-section-505b2-output/final-guidance-industry-applications-covered-section-505b2-